Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aptevo Therapeutics ( (APVO) ) has issued an announcement.
On January 8, 2026, Aptevo Therapeutics entered into a $60 million standby equity purchase and equity line of credit arrangement with Yorkville Advisors, giving the company the right, but not the obligation, to sell common shares over 36 months under market-based pricing, within Nasdaq share caps and a 9.99% ownership limit for Yorkville. The structure, which carries relatively modest fees, is expected—together with Aptevo’s existing cash—to extend the company’s funding runway into 2029, supporting ongoing and planned clinical and preclinical development of its multispecific oncology pipeline while preserving strategic flexibility and incremental, discretionary access to capital for general corporate and R&D purposes.
The most recent analyst rating on (APVO) stock is a Hold with a $0.59 price target. To see the full list of analyst forecasts on Aptevo Therapeutics stock, see the APVO Stock Forecast page.
Spark’s Take on APVO Stock
According to Spark, TipRanks’ AI Analyst, APVO is a Neutral.
The score is primarily held down by very weak financial performance (no revenue, large ongoing losses, and heavy cash burn) and bearish technicals (price far below key moving averages with negative momentum). A positive offset comes from encouraging clinical trial news, but it does not outweigh the current profitability and funding-risk profile.
To see Spark’s full report on APVO stock, click here.
More about Aptevo Therapeutics
Aptevo Therapeutics Inc. (Nasdaq: APVO) is a clinical-stage biotechnology company developing novel bispecific and trispecific immunotherapies for cancer, built on its proprietary ADAPTIR and ADAPTIR-FLEX platforms. Its lead candidate mipletamig, a CD123 x CD3 bispecific with orphan drug designation for acute myeloid leukemia, is in a Phase 1b/2 frontline AML trial, alongside ALG.APV-527 for solid tumors and a portfolio of six preclinical multispecific CD3-engaging and 4-1BB–targeting programs aimed at a range of solid tumors.
Average Trading Volume: 76,490
Technical Sentiment Signal: Strong Sell
Current Market Cap: $8.34M
For detailed information about APVO stock, go to TipRanks’ Stock Analysis page.